Insights & Updates

The transition from preclinical promise to clinical efficacy, the so-called "Translational Gap", remains the most perilous stage of drug development. Nowhere is this chasm wider than in neurodegeneration, where billions of dollars and years of research are lost when promising candidates fail in late-stage trials. The fundamental reason is often a stark divergence between the simplified environments of preclinical models and the complex, heterogeneous reality of human disease.